<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00361439</url>
  </required_header>
  <id_info>
    <org_study_id>14757A (P04908)</org_study_id>
    <secondary_id>IRB #14757A</secondary_id>
    <nct_id>NCT00361439</nct_id>
  </id_info>
  <brief_title>Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis</brief_title>
  <official_title>Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with allergies frequently complain of a loss or reduction in the sense of smell.

      In this study, the investigators propose to perform a randomized, double blind, placebo
      controlled parallel study of subjects with nasal allergies and decreased smell to determine
      the effect of a treatment for allergies on the sense of smell.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped early due to slow accrual.
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological Findings</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of eosinophils per high-powered field (HPF) in olfactory biopsy taken after 2 weeks of study treatment (higher values indicate greater inflammation); average of three HPF reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Nasal Symptom Score at 2 Weeks</measure>
    <time_frame>baseline and 2 weeks</time_frame>
    <description>A decrease in scores between visits signifies an improvement in nasal symptoms. The total nasal symptom score can range from 0 to 27.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nasal Peak Inspiratory Flow at 2 Weeks</measure>
    <time_frame>baseline and 2 weeks</time_frame>
    <description>An increase between visits indicates improved nasal airflow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Eosinophils at 2 Weeks</measure>
    <time_frame>baseline and 2 weeks</time_frame>
    <description>A decrease between visits signifies a reduction in inflammation.
Calculated from cytology specimens obtained by lavage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Mometasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mometasone intranasal steroid therapy daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 puffs of placebo spray in each nostril once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone</intervention_name>
    <description>2 puffs in each nostril once daily of nasal spray</description>
    <arm_group_label>Mometasone</arm_group_label>
    <other_name>Nasonex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 puffs in each nostril once daily of nasal spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females between 18 and 59 years of age.

          2. Seasonal allergic rhinitis by clinical history, with symptoms of impaired olfaction.

          3. Positive skin or RAST test to allergen.

          4. Symptoms of olfactory dysfunction.

          5. No significant history of chronic sinusitis.

        Exclusion Criteria:

          1. Women of childbearing potential not using the contraception method(s) (Birth control
             pills, depo Provera, double barrier) as well as women who are breastfeeding.

          2. Patients with severe medical condition(s) that in the view of the investigator
             prohibits participation in the study (heart, lung, kidney, neurological, oncologic or
             liver disease).

          3. Use of any other investigational agent in the last 30 days.

          4. Absence of olfactory or nasal symptoms.

          5. Use of medications that may affect olfaction.

          6. Medical conditions that may affect olfaction.

          7. Smoking.

          8. URI at the time of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayant M Pinto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2006</study_first_submitted>
  <study_first_submitted_qc>August 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2006</study_first_posted>
  <results_first_submitted>July 20, 2012</results_first_submitted>
  <results_first_submitted_qc>July 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2012</results_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled during relevant allergy seasons in Chicago, IL, from 2006 to 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Mometasone</title>
          <description>Active intranasal steroid therapy daily for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>2 puffs of placebo spray once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mometasone</title>
          <description>Active intranasal steroid therapy daily for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>2 puffs of placebo spray once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="24" upper_limit="49"/>
                    <measurement group_id="B2" value="38" lower_limit="23" upper_limit="52"/>
                    <measurement group_id="B3" value="39" lower_limit="23" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Allergen sensitivity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ragweed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Histological Findings</title>
        <description>Number of eosinophils per high-powered field (HPF) in olfactory biopsy taken after 2 weeks of study treatment (higher values indicate greater inflammation); average of three HPF reported</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone</title>
            <description>Active intranasal steroid therapy daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 puffs of placebo spray once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Histological Findings</title>
          <description>Number of eosinophils per high-powered field (HPF) in olfactory biopsy taken after 2 weeks of study treatment (higher values indicate greater inflammation); average of three HPF reported</description>
          <units>eosinophils per HPF</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.167" lower_limit="0" upper_limit="1.33"/>
                    <measurement group_id="O2" value="2.67" lower_limit="1.33" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Nasal Symptom Score at 2 Weeks</title>
        <description>A decrease in scores between visits signifies an improvement in nasal symptoms. The total nasal symptom score can range from 0 to 27.</description>
        <time_frame>baseline and 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone</title>
            <description>Active intranasal steroid therapy daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 puffs of placebo spray once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Nasal Symptom Score at 2 Weeks</title>
          <description>A decrease in scores between visits signifies an improvement in nasal symptoms. The total nasal symptom score can range from 0 to 27.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" lower_limit="-18" upper_limit="-2"/>
                    <measurement group_id="O2" value="-5" lower_limit="-13" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.023</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nasal Peak Inspiratory Flow at 2 Weeks</title>
        <description>An increase between visits indicates improved nasal airflow.</description>
        <time_frame>baseline and 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone</title>
            <description>Active intranasal steroid therapy daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 puffs of placebo spray once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nasal Peak Inspiratory Flow at 2 Weeks</title>
          <description>An increase between visits indicates improved nasal airflow.</description>
          <units>liters per minute</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="-3.3" upper_limit="56.7"/>
                    <measurement group_id="O2" value="-37.5" lower_limit="-58" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Eosinophils at 2 Weeks</title>
        <description>A decrease between visits signifies a reduction in inflammation.
Calculated from cytology specimens obtained by lavage.</description>
        <time_frame>baseline and 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone</title>
            <description>Active intranasal steroid therapy daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 puffs of placebo spray once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Eosinophils at 2 Weeks</title>
          <description>A decrease between visits signifies a reduction in inflammation.
Calculated from cytology specimens obtained by lavage.</description>
          <units>percentage of eosinophils</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" lower_limit="-12.9" upper_limit="4.2"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-53.9" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.010</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the two weeks of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mometasone</title>
          <description>Active intranasal steroid therapy daily for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>2 puffs of placebo spray once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to slow accrual</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jayant Pinto, MD</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-6727</phone>
      <email>jpinto@surgery.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

